Prevention of Paclitaxel-induced Allodynia by Minocycline: Effect on Loss of Peripheral Nerve Fibers and Infiltration of Macrophages in Rats
Overview
Affiliations
Background: Although paclitaxel is a frontline antineoplastic agent for treatment of solid tumors, the paclitaxel-evoked pain syndrome is a serious problem for patients. There is currently no valid drug to prevent or treat the paclitaxel-induced allodynia, partly due to lack of understanding regarding the cellular mechanism. Studies have shown that minocycline, an inhibitor of microglia/macrophage, prevented neuropathic pain and promoted neuronal survival in animal models of neurodegenerative disease. Recently, Cata et al also reported that minocycline inhibited allodynia induced by low-dose paclitaxel (2 mg/kg) in rats, but the mechanism is still unclear.
Results: Here, we investigate by immunohistochemistry the change of intraepidermal nerve fiber (IENF) in the hind paw glabrous skin, expression of macrophage and activating transcription factor 3 (ATF3) in DRG at different time points after moderate-dose paclitaxel treatment (cumulative dose 24 mg/kg; 3 × 8 mg/kg) in rats. Moreover, we observe the effect of minocycline on the IENF, macrophages and ATF3. The results showed that moderate-dose paclitaxel induced a persisted, gradual mechanical allodynia, which was accompanied by the loss of IENF in the hind paw glabrous skin and up-regulation of macrophages and ATF3 in DRG in rats. The expressions of ATF3 mainly focus on the NF200-positive cells. More importantly, we observed that pretreatment of minocycline at dose of 30 mg/kg or 50 mg/kg, but not 5 mg/kg, prevented paclitaxel-evoked allodynia. The evidence from immunohistochemistry showed that 30 mg/kg minocycline rescued the degeneration of IENF, attenuated infiltration of macrophages and up-regulation of ATF3 induced by paclitaxel treatment in rats.
Conclusions: Minocycline prevents paclitaxel-evoked allodynia, likely due to its inhibition on loss of IENF, infiltration of macrophages and up-regulation of ATF3 in rats. The finding might provide potential target for preventing paclitaxel-induced neuropathic pain.
Alsalem M, Ellaithy A, Bloukh S, Haddad M, Saleh T Support Care Cancer. 2024; 32(1):85.
PMID: 38177894 DOI: 10.1007/s00520-023-08287-0.
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.
Chen C, Zirpoli G, Barlow W, Budd G, McKiver B, Pusztai L J Natl Compr Canc Netw. 2023; 21(11):1172-1180.e3.
PMID: 37935109 PMC: 10976748. DOI: 10.6004/jnccn.2023.7062.
Alhadlaq M, Masocha W Int J Mol Sci. 2023; 24(16).
PMID: 37628987 PMC: 10454318. DOI: 10.3390/ijms241612805.
Kume M, Ahmad A, DeFea K, Vagner J, Dussor G, Boitano S J Pain. 2023; 24(11):1980-1993.
PMID: 37315729 PMC: 10615692. DOI: 10.1016/j.jpain.2023.06.006.
Guimaraes R, Anibal-Silva C, Davoli-Ferreira M, Gomes F, Mendes A, Cavallini M Elife. 2023; 12.
PMID: 37254842 PMC: 10266765. DOI: 10.7554/eLife.78515.